Crystal Bio Solutions built its business around a stubborn truth of drug development: the clinical decision can be only as good as the assay beneath it. Its new bet is to keep the test, the model, and the regulatory argument in the same conversation.
The Montreal-area CRO escaped the commodity economics of generic-drug testing by stitching labs, clinics and manufacturing into one early-development platform. Its wager is simple: the science need not move recklessly for the program to move faster.